During the past decade, Myongji Hospital conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 7 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 3 clinical trials were completed. i.e. 30% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Myongji Hospital" #1 sponsor was "Asan Medical Center" with 3 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "Chong Kun Dang Pharmaceutical" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored and "Inha University Hospital" with 3 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Myongji Hospital" #1 collaborator was "Daiichi Sankyo Korea Co., Ltd." with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Korea Otsuka Pharmaceutical Co., Ltd." with 2 trials as a collaborator, "Bobath Memorial Hospital" with 1 trials as a collaborator and "Chung-Ang University Hosptial, Chung-Ang University College of Medicine" with 1 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 31 trials.

According to Clinical.Site data, the most researched conditions in "Myongji Hospital" are "Alzheimer Disease" (3 trials), "Alzheimer's Disease" (3 trials), "Diabetes Mellitus, Type 2" (3 trials), "Ischemic Stroke" (3 trials) and "Brain Ischemia" (2 trials). Many other conditions were trialed in "Myongji Hospital" in a lesser frequency.

Most popular intervention types in "Myongji Hospital" are "Drug" (34 trials), "Device" (3 trials), "Biological" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Gantenerumab" (2 trials), "bococizumab (PF-04950615)" (2 trials), "Aggressive BP lowering" (1 trials) and "Alcaftadine Ophthalmic Solution 0.25%" (1 trials). Other intervention names were less common.

The vast majority of trials in "Myongji Hospital" are 42 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Myongji Hospital". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Myongji Hospital, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Myongji Hospital, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 13 trials, and there were also 2 trials that are defined as “Not Applicable".